Navigation Links
Vasogen Provides Update on ACCLAIM II Program
Date:3/3/2008

MISSISSAUGA, ON, March 3 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today provided an update on ACCLAIM II, a clinical trial which is being planned to support an application for U.S. market approval of the Celacade(TM) System for the treatment of patients with New York Heart Association (NYHA) Class II heart failure.

The Company announced in December that the FDA was examining its internal jurisdiction over Vasogen's Celacade System in the context of a newly issued draft guidance document to assess whether this document was relevant to Celacade. Previously, the FDA's Center for Devices and Radiological Health (CDRH) acted as lead reviewer of Celacade, with input from the Center for Biologics Evaluation and Research (CBER). The FDA has confirmed that Celacade will remain regulated as a medical device; however, CBER will be the lead reviewer of the Celacade technology, with CDRH providing input. The transition process from CDRH to CBER is now complete.

As part of the transition, on February 29, CDRH communicated to the Company that they now disagree with the use of a Bayesian approach because of a concern with recruiting a heterogeneous study population between ACCLAIM and ACCLAIM II. This is contrary to the FDA's original communication to Vasogen recommending a Bayesian study design, and, as part of its ongoing informal dialogue, the Company plans to provide the FDA with its position regarding the ACCLAIM II study population.

"The FDA's comments with respect to utilizing a Bayesian approach for the design of ACCLAIM II are surprising," commented Chris Waddick, President and CEO of Vasogen. "Our immediate focus will be to engage in discussions with the FDA to clarify their position on the proposed ACCL
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   SurePure, Inc ... photopurification, announced today that the Company has completed ... continued trading of SurePure ("SURP") securities on OTCQB, ... for entrepreneurial and development stage companies. ... standards and eligibility requirements designed to improve marketplace ...
(Date:3/27/2015)... 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... focus on China , today reported ... December 31, 2014.  The Company reported ... share, for the three months ended December 31, 2014.  ...
(Date:3/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... including the appointment of auditors, its annual and special ... "Meeting") was adjourned, as previously disclosed on March 25, ... Toronto time). The date of the ... The Meeting will reconvene at the offices of the ...
(Date:3/26/2015)... March 26, 2015 Neogen Corporation (NASDAQ: ... the third quarter of fiscal 2015, which ended Feb. ... prior year,s $6,575,000. Earnings per share in the current ... Current year-to-date net income increased 17% over prior year ... or $0.56 per share, for the same period a ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6SQI Diagnostics Inc. Announces Adjournment of Meeting 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... Corporation (NYSE: SHP ) ("ShangPharma" or ... research and development outsourcing company, today announced that ... Commerce as one of the Top Ten Leading ... top ten companies were announced at the Fourth ...
... development of the first self-powered nano-device that can transmit ... ACS,s journal Nano Letters , they say it ... implantable medical sensors, airborne and stationary surveillance cameras and ... independently without batteries on energy collected from the environment. ...
... June 15, 2011 Solid grounding in science is ... of American leaders. From biochemists and pharmacists to physician ... States job market lies in the fields of healthcare ... online survey conducted by Harris Interactive for University ...
Cached Biology Technology:ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise 2Careers in Healthcare and Science? "Not Interested" Say Half of U.S. Teens 2Careers in Healthcare and Science? "Not Interested" Say Half of U.S. Teens 3Careers in Healthcare and Science? "Not Interested" Say Half of U.S. Teens 4
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/11/2015)... , March 11, 2015   The Sync ... platform to scientifically measure and harness music to ... real-time biometrics and objective measurements of physiology, enabling ... at scale in large populations. It is designed ... and clinicians perform rigorous studies and accelerate the ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... cracked the problem of pod shatter in brassica crops such ... are prone to shatter, causing a 10-25% loss of seeds ... producing a hormone in a specific region of the fruit, ... plant Arabidopsis , completely sealing the seeds inside," says ...
... Paul Anastas, Yale,s Teresa and H. John Heinz III ... to lead the U.S. Environmental Protection Agency,s (EPA,s) Office ... of the Center for Green Chemistry & Green Engineering ... chemical engineering and the School of Forestry & Environmental ...
... alleviate diseases associated with menopause, she didn,t realize her ... hundreds of millions of people. The Northern Arizona ... University of Arizona identified a nontoxic chemical technology that ... feast on crops intended for human consumption. ...
Cached Biology News:Shatter-resistant brassicas 2'Father of green chemistry' Paul Anastas to head EPA research 2NAU discovery could help feed millions 2NAU discovery could help feed millions 3
The AVR9-8 stream-select valve is a 9-port, 8-position valve for use with the BioLogic DuoFlow system. This valve is used for high-pressure stream selection....
... BioGenex Super Sensitive MultiLink IHC ... species-specific secondary antibodies, labeled with ... to the bound primary antibody, ... a Streptavidin-Enzyme conjugate. This kit ...
Sf21 Insect Cells (Live) in Max-XP Medium...
EZ-DeWax is a one-step solution that simultanously removes paraffin from and rehydrates formalin-fixed, paraffin embedded tissue...
Biology Products: